27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
- Sage Therapeutics Inc (NASDAQ:SAGE) and Biogen Inc (NASDAQ:BIIB) presented additional data from the Phase 3 SKYLARK Study of zuranolone in adult women with postpartum depression (PPD).
- The SKYLARK Study, as previously reported, achieved the primary and all key secondary endpoints.
- Zuranolone 50 mg showed a statistically significant and clinically meaningful improvement in depressive symptoms at Day 15, the primary endpoint, compared to the placebo.
- In the presentation at the European College of Neuropsychopharmacology Congress, additional secondary endpoint data demonstrated that a higher proportion of patients in the zuranolone 50 mg arm achieved a HAMD-17 response compared with the placebo arm.
- Data also showed that a higher proportion of patients in the zuranolone arm achieved HAMD-17 remission than in the placebo arm.
- Zuranolone was generally well-tolerated, with a safety profile consistent with that observed in the clinical development program.
- Sage Therapeutics and Biogen have initiated a rolling submission to the FDA and plan to complete the filing in 2H of 2022.
- Price Action: SAGE shares are down 0.03% at $37.92, and BIIB stock is up 1.05% at $267.40 on the last check Monday.
27% profit every 20 days?
This is what Nic Chahine averages with his option buys. Not selling covered calls or spreads… BUYING options. Most traders don’t even have a winning percentage of 27% buying options. He has an 83% win rate. Here’s how he does it.
ENTER TO WIN $500 IN STOCK OR CRYPTO
Enter your email and you'll also get Benzinga's ultimate morning update AND a free $30 gift card and more!